Centrosome Dysfunction examines the critical role of the centrosome—the major microtubule-organizing center in animal cells—in neurological disorders and neurodegenerative diseases. This page covers centrosome structure, its functions in cell division and intracellular transport, and its involvement in conditions like microcephaly, Alzheimer's disease, Parkinson's disease, and ALS. [@conduit2015]
The centrosome is a non-membrane-bound organelle that serves as the primary microtubule-organizing center in animal cells. It plays essential roles in cell division, intracellular transport, and ciliogenesis. Dysfunction of the centrosome has been increasingly recognized as a factor in various neurological disorders, including microcephaly, lissencephaly, and neurodegenerative diseases. [@nigg2018]
The centrosome is the major microtubule-organizing center in animal cells, playing critical roles in cell division, intracellular transport, and ciliogenesis. Centrosome dysfunction has been implicated in various neurological disorders and neurodegenerative diseases. [@bettencourtdias2007]
Centrosome dysfunction represents an emerging therapeutic target in neurodegeneration, though clinical translation remains in early stages. Unlike well-established pathways such as amyloid or tau, centrosome-based therapeutics have not yet reached clinical trials for Alzheimer's or Parkinson's disease. However, the fundamental role of centrosome integrity in neuronal survival makes this pathway increasingly attractive for drug development.
The therapeutic approaches currently under investigation can be categorized into three main strategies:
1. Kinase Inhibitors Targeting Centrosome Regulators
The polo-like kinase 4 (PLK4) inhibitor Centrinone (also known as LKS-1) has demonstrated potent centrosome ablation effects in preclinical models. While initially developed for cancer therapy due to its ability to induce centrosome depletion and mitotic catastrophe in tumor cells, this compound has potential implications for neurodegenerative disease through its effects on cell cycle regulation. In neurons, aberrant cell cycle re-entry is a well-documented phenomenon in AD and PD brains, and modulating centrosome-dependent cell cycle checkpoints could potentially prevent pathological cell cycle activation. [@lancini2020]
2. Gene Therapy Approaches
Mutations in primary microcephaly (MCPH) genes such as MCPH1, ASPM, and WDR62 cause neurodevelopmental defects, but their dysfunction may also contribute to age-related neurodegeneration. AAV-mediated gene delivery of wild-type MCPH genes represents a potential therapeutic strategy, though this remains at the preclinical stage. The challenge lies in achieving appropriate expression levels in specific neuronal populations without disrupting normal centrosome function. [@mohammad2022]
3. Centrosome Stabilization Strategies
Rather than inhibiting centrosome function, an alternative approach involves stabilizing centrosome integrity to prevent age-related centrosome defects. Small molecules that enhance centriolar cohesion or protect pericentriolar material (PCM) from degradation could preserve proper microtubule organization and intracellular transport in neurons. Compounds targeting centrosome-associated proteins such as centrin, nexin, and pericentrin are under investigation. [@gallet2021]
No validated biomarkers specifically targeting centrosome dysfunction currently exist for clinical use. However, several research-stage biomarkers show promise:
As of 2026, no registered clinical trials specifically target centrosome dysfunction in neurodegenerative diseases. The field remains at preclinical/early translational stages, with most research focused on:
This represents a significant gap in the therapeutic pipeline and an opportunity for clinical development.
The clinical relevance of centrosome dysfunction in neurodegeneration includes several aspects:
Cognitive and Motor Outcomes: If centrosome-based therapeutics prove effective, they could potentially:
Diagnostic Potential: Centrosome biomarkers could contribute to:
Challenges: The patient community faces several challenges:
Key Challenges:
Target validation: The causal relationship between centrosome dysfunction and neurodegeneration requires more definitive evidence. While centrosome abnormalities are observed in AD and PD brains, it remains unclear whether these are primary drivers or secondary effects.
Therapeutic window: Centrosome function is essential for cell division and cellular homeostasis. Broad inhibition could have toxic effects, requiring highly specific targeting.
Delivery to neurons: The blood-brain barrier presents a challenge for small molecule delivery. Novel approaches such as focused ultrasound or RMT (receptor-mediated transcytosis) may be needed. See Blood-Brain Barrier Biology for current delivery strategies.
Biomarker development: Validation of centrosome-specific biomarkers requires large longitudinal studies.
Future Directions:
Combination therapies: Centrosome-targeted agents could be combined with existing AD/PD therapeutics targeting amyloid, tau, or alpha-synuclein.
Personalized medicine: Genetic variants in centrosome-associated genes may identify patients who would benefit most from centrosome-targeted interventions.
Repurposing opportunities: PLK4 inhibitors developed for cancer could be repurposed for neurodegeneration if safety profiles are acceptable.
Stem cell-based approaches: iPSC models from patients with centrosome-related genetic variants could enable patient-specific drug testing.
The centrosome represents a promising but underdeveloped therapeutic target in neurodegeneration. While clinical translation is years away, the growing understanding of centrosome function in neuronal health makes this pathway increasingly attractive for future drug development.
Centrosome abnormalities are increasingly recognized in Alzheimer's disease (AD) brains, though the causal relationship remains under investigation. [@wang2019]
Multiple studies have documented centrosome amplification in AD neurons:
Tau Phosphorylation Effects:
Amyloid-β Connections:
The cell cycle re-entry hypothesis proposes that centrosome dysfunction contributes to aberrant neuronal cell cycle activity:
LRRK2 (Leucine-Rich Repeat Kinase 2) localizes to the centrosome and centrosomal proteins: [@ye2019]
Several connections exist between mitochondrial dysfunction and centrosome abnormalities in PD:
Alpha-synuclein aggregation affects centrosome function:
The dynein-dynactin complex is crucial for axonal transport and centrosome function: [@mohan2019]
TDP-43 aggregation, the hallmark of ALS/FTD, affects centrosomal proteins:
The centrosome plays a role in presynaptic biology:
The centrosome and primary cilium are functionally interconnected: [@etter2019] [@bhong2016]
Primary cilia perform important neuronal functions:
Ciliopathy genes are linked to neurodevelopmental disorders:
The centrosome organizes the microtubule network essential for intracellular transport: [@perez2015] [@baas2016]
Despite significant progress, key questions remain:
Causality: Are centrosome abnormalities primary drivers or secondary effects?
Therapeutic Window: How can we target centrosome function without affecting cell division?
Biomarkers: What reliable biomarkers reflect centrosome dysfunction in patients?
Cell Type Specificity: Why are certain neurons more vulnerable?
Developmental vs. Degenerative: How do centrosome defects in development differ from aging?
Combination Therapies: Can centrosome-targeted approaches be combined with existing treatments?
Kinase Inhibitors:
Stabilizing Agents:
Gene Therapy:
The study of Centrosome Dysfunction has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@arquint2014]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [@badano2015]
🟡 Moderate-High Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 32 references |
| Replication | 15% |
| Effect Sizes | 40% |
| Contradicting Evidence | 10% |
| Mechanistic Completeness | 70% |
Overall Confidence: 65%